These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1280675)

  • 1. Suramin for prostate carcinoma.
    Harland SJ
    J Clin Oncol; 1992 Dec; 10(12):1985-6. PubMed ID: 1280675
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
    Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
    J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Workshop on suramin with emphasis on prostate cancer: re-evaluation of response criteria.
    van Rijswijk RE; Cvitkovic E; Wagstaff J; Myers CE
    Eur J Cancer; 1993; 29A(3):298-300. PubMed ID: 7691118
    [No Abstract]   [Full Text] [Related]  

  • 4. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
    Small EJ; Meyer M; Marshall ME; Reyno LM; Meyers FJ; Natale RB; Lenehan PF; Chen L; Slichenmyer WJ; Eisenberger M
    J Clin Oncol; 2000 Apr; 18(7):1440-50. PubMed ID: 10735891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
    Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
    Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
    Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
    J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
    Eisenberger MA; Nelson WG
    J Natl Cancer Inst; 1996 Jun; 88(12):779-81. PubMed ID: 8637038
    [No Abstract]   [Full Text] [Related]  

  • 8. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
    Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
    J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
    Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
    J Clin Oncol; 1995 Dec; 13(12):2944-53. PubMed ID: 8523059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suramin and prostate cancer: where do we go from here?
    Clark JW; Chabner BA
    J Clin Oncol; 1995 Sep; 13(9):2155-7. PubMed ID: 7666073
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.
    LaRocca RV; Cooper MR; Uhrich M; Danesi R; Walther MM; Linehan WM; Myers CE
    Urol Clin North Am; 1991 Feb; 18(1):123-9. PubMed ID: 1992566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American studies on suramin therapy in hormone resistant prostate cancer.
    Rosen P; Belldegrun A
    Cancer Surv; 1995; 23():231-4. PubMed ID: 7621461
    [No Abstract]   [Full Text] [Related]  

  • 13. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
    Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
    J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.
    Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
    Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):631-4. PubMed ID: 9681533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suramin's development: what did we learn?
    Kaur M; Reed E; Sartor O; Dahut W; Figg WD
    Invest New Drugs; 2002 May; 20(2):209-19. PubMed ID: 12099581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
    Myers C; Cooper M; Stein C; LaRocca R; Walther MM; Weiss G; Choyke P; Dawson N; Steinberg S; Uhrich MM
    J Clin Oncol; 1992 Jun; 10(6):881-9. PubMed ID: 1375283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
    Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
    Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigrowth factor strategies.
    Myers C; Trepel J; Sartor O; Cooper M; Ranson M; Toko T; Linehan MW
    Cancer; 1993 Feb; 71(3 Suppl):1172-8. PubMed ID: 7679041
    [No Abstract]   [Full Text] [Related]  

  • 19. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
    Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
    J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suramin.
    Eisenberger MA; Sinibaldi V; Reyno L
    Cancer Pract; 1995; 3(3):187-9. PubMed ID: 7599677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.